Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment

(2020) Anuja Sathe et al.   CLINICAL CANCER RESEARCH

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.

(2020) Elizabeth Catherine Smyth et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

(2020) Charles S. Fuchs et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

(2020) Yelena Y Janjigian et al.   LANCET ONCOLOGY

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer

(2020) Takaomi Hagi et al.   BRITISH JOURNAL OF CANCER

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

(2020) V. Gambardella et al.   CANCER TREATMENT REVIEWS

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types

(2020) Gabriel S Krigsfeld et al.   JOURNAL OF CLINICAL PATHOLOGY

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

(2020) Akihito Kawazoe et al.   LANCET ONCOLOGY

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

(2020) Daniel V T Catenacci et al.   LANCET ONCOLOGY

Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy

(2020) Katherine I Zhou et al.   CLINICAL CANCER RESEARCH

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

(2020) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

(2019) R Sundar et al.   ANNALS OF ONCOLOGY

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

(2019) Yu Kato et al.   PLoS One

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

(2019) Yung-Jue Bang et al.   Future Oncology

A C-X-C chemokine receptor type 2-dominated crosstalk between tumor cells and macrophages drives gastric cancer metastasis

(2019) Zhijun Zhou et al.   CLINICAL CANCER RESEARCH

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma

(2019) V Gambardella et al.   ANNALS OF ONCOLOGY

Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

(2019) Zev A. Wainberg et al.   JOURNAL OF CLINICAL ONCOLOGY

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

(2019) Yelena Yuriy Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

(2019) Yasuhide Yamada et al.   Lancet Gastroenterology & Hepatology

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

(2019) Andrea Necchi et al.   EUROPEAN UROLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

(2019) Sylvie Lantuejoul et al.   Journal of Thoracic Oncology

Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients

(2018) Michael Davidson et al.   Clinical Colorectal Cancer

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

(2018) Mohamed E. Salem et al.   MOLECULAR CANCER RESEARCH

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

(2018) Valentina Fanotto et al.   ONCOLOGIST

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

(2018) Y -J Bang et al.   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

(2018) N Boku et al.   ANNALS OF ONCOLOGY

A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies

(2018) Cory Batenchuk et al.   JOURNAL OF CLINICAL PATHOLOGY

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET ONCOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Integrated genomic characterization of oesophageal carcinoma

(2017)   NATURE

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) E. C. Smyth et al.   ANNALS OF ONCOLOGY

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) F. Lordick et al.   ANNALS OF ONCOLOGY

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data

(2015) Lisa M. Hess et al.   Gastric Cancer

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

(2014) X Su et al.   BRITISH JOURNAL OF CANCER

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

(2014) Suling J Lin et al.   GUT

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

(2013) N C T van Grieken et al.   BRITISH JOURNAL OF CANCER

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

(2012) A. M. Dulak et al.   CANCER RESEARCH

E-cadherin dysfunction in gastric cancer - Cellular consequences, clinical applications and open questions

(2012) Patrícia Carneiro et al.   FEBS LETTERS

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE